Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.56 |
| ▸ | NAT1 | P18440 | 2/20 | 0.56 |
| ▸ | MAX | P61244 | 2/20 | 0.56 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.52 |
| ▸ | CRHBP | P24387 | 2/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 6/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.47 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244675 | 1.00 | MYC (0.56) | MYCNAT1MAXPTP4A3CRHBP | |
| SCHEMBL1243983 | 0.78 | PIM1 (0.55) | NAT1PTP4A3PIK3CGADAMTS5PIM1 | |
| SCHEMBL1243984 | 0.78 | PIM1 (0.55) | NAT1PTP4A3PIK3CGADAMTS5PIM1 | |
| SCHEMBL1243980 | 0.78 | PIM1 (0.55) | NAT1PTP4A3PIK3CGADAMTS5PIM1 | |
| SCHEMBL1249067 | 0.73 | NAT1 (1.00) | MYCNAT1MAXCRHBPCRHR2 | |
| SCHEMBL1249069 | 0.73 | NAT1 (1.00) | MYCNAT1MAXCRHBPCRHR2 | |
| SCHEMBL20816059 | 0.73 | NAT1 (1.00) | MYCNAT1MAXCRHBPCRHR2 | |
| SCHEMBL1242209 | 0.73 | HSD17B10 (0.38) | — | |
| SCHEMBL8172015 | 0.72 | MYC (0.61) | MYCNAT1MAXPTP4A3CRHBP | |
| SCHEMBL2224453 | 0.72 | NAT1 (0.66) | NAT1PTP4A3PIM1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2057162-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | Sepracor Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005456-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | DAO, DDO, AOX1 | MYC 3400/4885NAT1 481/4885MAX 916/4885 |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | DAO, DDO, AOX1 | MYC 3145/4885NAT1 694/4885MAX 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.